Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

BioScience Health Innovations (BHIC) EBT Margin (2023 - 2026)

BioScience Health Innovations has reported EBT Margin over the past 4 years, most recently at 30.62% for Q1 2026.

  • Quarterly EBT Margin fell 6540.0% to 30.62% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 8.97% through Mar 2026, down 2702.0% year-over-year, with the annual reading at 3.32% for FY2025, 201.0% up from the prior year.
  • EBT Margin was 30.62% for Q1 2026 at BioScience Health Innovations, up from 43.66% in the prior quarter.
  • Over five years, EBT Margin peaked at 34.78% in Q1 2025 and troughed at 218.68% in Q1 2023.
  • The 4-year median for EBT Margin is 12.64% (2023), against an average of 30.52%.
  • Year-over-year, EBT Margin surged 19946bps in 2024 and then crashed -6540bps in 2026.
  • A 4-year view of EBT Margin shows it stood at 12.64% in 2023, then soared by 31bps to 8.66% in 2024, then tumbled by -404bps to 43.66% in 2025, then increased by 30bps to 30.62% in 2026.
  • Per Business Quant, the three most recent readings for BHIC's EBT Margin are 30.62% (Q1 2026), 43.66% (Q4 2025), and 0.78% (Q3 2025).